Drug Search Results
More Filters [+]

Dasatinib

Alternative Names: dasatinib, sprycel, bms-354825, DAZATINIB
Latest Update: 2024-02-14
Latest Update Note: Clinical Trial Update

Product Description

Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects. Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607063.html)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dasatinib

Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Jordan, Korea, Lebanon, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 31

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Chronic Myeloid Leukemia

Phase 2: Bone Diseases, Metabolic|HIV Infections|Inflammation|Leukemia|Lymphoma, Non-Hodgkin|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Neuroblastoma|Non-Small-Cell Lung Cancer|Nose Cancer|Oncology Unspecified|Osteoporosis|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer

Phase 1: Acute Myeloid Leukemia|B-Cell Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Healthy Volunteers|Leukemia, Plasma Cell|Lymphoid Leukemia|Lymphoma, B-Cell|Mesothelioma|Multiple Myeloma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Waldenstrom Macroglobulinemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HEM-iSMART B

P2

Not yet recruiting

Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2030-10-01

jRCT2021210060

P3

Active, not recruiting

Chronic Myeloid Leukemia

2029-03-31

UMCC 2018.144

P2

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2026-01-01

KISS

P2

Active, not recruiting

Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia

2025-12-31

Recent News Events